This finding is consistent with established clinical evidence indicating that insulin-treated GDM reflects more advanced metabolic impairment, greater insulin resistance, and higher glycemic variability, all of which increase the complexity of daily self-management and the need for intensified monitoring and support [8,9,11]. This evidence concerns the gene INS and Insulin resistance.